• Number of Subjects With Severe Rotavirus Gastroenteritis Caused by the Circulating Wild-type Rotavirus Strain, Classified by Rotavirus Type [ Time Frame: From 2 weeks after the last vaccine or placebo dose up to 1 year of age ] [ Designated as safety issue: No ]
• Number of Subjects Reporting Any Rotavirus Gastroenteritis Caused by the Circulating Wild-type Rotavirus Strain [ Time Frame: From 2 weeks after the last vaccine or placebo dose up to 1 year of age ] [ Designated as safety issue: No ]
• Number of Subjects With Severe Rotavirus Gastroenteritis Caused by the Circulating Wild-type Rotavirus Strain [ Time Frame: From the first vaccine or placebo dose up to 1 year of age ] [ Designated as safety issue: No ]
• In South Africa, Number of Subjects With Severe Rotavirus Gastroenteritis Caused by the Circulating Wild-type Rotavirus Strain [ Time Frame: From 2 weeks after the third dose of vaccine or placebo up to 1 year of age ] [ Designated as safety issue: No ]
• Number of Subjects Reporting Severe Gastroenteritis of Any Cause [ Time Frame: From 2 weeks after the last vaccine or placebo dose up to 1 year of age ] [ Designated as safety issue: No ]
• For Subjects in Cohort 2 South Africa and the Cohort in Malawi:Occurrence of Severe RV GE Caused by the Circulating Wild-type RV Strains [ Time Frame: During the period from 2 weeks after the last dose of HRV vaccine or placebo until Visit 7, and from Visit 6 to Visit 7. ] [ Designated as safety issue: No ]
• For Subjects in Cohort 2 South Africa and the Cohort in Malawi: Occurrence of Hospitalisation and/or Supervised Re-hydration Therapy in a Medical Facility for RV GE Caused by the Circulating Wild-type RV Strains [ Time Frame: During the period from 2 weeks after the last dose of HRV vaccine or placebo until Visit 7, and from Visit 6 to Visit 7. ] [ Designated as safety issue: No ]
• For Subjects in Cohort 2 South Africa and the Cohort in Malawi: Occurrence of Severe RV GE Caused by the Circulating Wild-type RV Strains of G1 Serotype [ Time Frame: During the period from 2 weeks after the last dose of HRV vaccine or placebo until Visit 7, and from Visit 6 to Visit 7. ] [ Designated as safety issue: No ]
• For Subjects in Cohort 2 South Africa and the Cohort in Malawi: Occurrence of Severe RV GE Caused by the Circulating Wild-type RV Strains of Non-G1 Serotype [ Time Frame: During the period from 2 weeks after the last dose of HRV vaccine or placebo until Visit 7, and from Visit 6 to Visit 7 ] [ Designated as safety issue: No ]
• Number of Subjects With Adverse Events (AEs) or Serious Adverse Events (SAEs) Leading to Drop Out [ Time Frame: From the first dose of vaccine or placebo up to 1 year of age ] [ Designated as safety issue: No ]
• Number of Subjects Reporting Serious Adverse Events (SAEs) [ Time Frame: From the first dose of vaccine or placebo up to 1 year of age ] [ Designated as safety issue: No ]
• Geometric Mean Concentration of Anti-rotavirus Immunoglobulin A (IgA) Antibodies in Initially Seronegative Subjects [ Time Frame: One month after the last vaccine dose ] [ Designated as safety issue: No ]
• Number of Seroconverted Subjects [ Time Frame: One month after the last vaccine or placebo dose ] [ Designated as safety issue: No ]
• Geometric Mean Concentration of Anti-rotavirus Immunoglobulin A (IgA) Antibodies [ Time Frame: One month after the last vaccine or placebo dose ] [ Designated as safety issue: No ]
• Number of Seropositive Subjects [ Time Frame: One month after the last vaccine or placebo dose ] [ Designated as safety issue: No ]
• Number of Subjects Hospitalized and/or With Supervised Re-hydration Therapy Due to Rotavirus Gastroenteritis (RV GE) Caused by the Circulating Wild-type Rotavirus Strain [ Time Frame: From 2 weeks after the last vaccine or placebo dose up to 1 year of age ] [ Designated as safety issue: No ]

The primary objective of this study is to determine if the GSK Biologicals' human rotavirus (HRV) vaccine (pooled HRV groups) given concomitantly with routine expanded program on immunisation (EPI) vaccinations can prevent severe rotavirus gastroenteritis (≥11 on the 20-point Vesikari scoring system [Ruuska, 1990]) caused by the circulating wild-type RV strains during the period from 2 weeks after the last dose of HRV vaccine or placebo until Visit 5.

The primary objective will be reached if the lower limit of the 95% confidence interval (CI) on vaccine efficacy is >0%.

The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep 2007.

The study will have three groups: Rotarix 3-Dose Group, Rotarix 2-Dose Group and Placebo Group. Three-dose immunisation will be administered in healthy infants at approximately 6, 10, and 14 weeks of age. Routine EPI vaccinations will be administered concomitantly with the study vaccines. This study will also evaluate immunogenicity and safety relative to the placebo.

• Prophylaxis Rotavirus
• Gastroenteritis Caused by Rotavirus

• Biological: Placebo
• Biological: Rotarix™

• Experimental: Subjects received 3 doses of Rotarix™ vaccine given concomitantly with routine EPI vaccines.
• Experimental: Subjects received 1 dose of placebo followed by 2 doses of Rotarix™ vaccine given concomitantly with routine EPI vaccines.
• Placebo Comparator: Subjects received 3 doses of placebo given concomitantly with routine EPI vaccines.

Inclusion Criteria:

• Subjects who the investigator believes that their parents/guardians can and will comply with the requirements of the protocol should be enrolled in the study.
• A male or female child between, and including, 5 and 10 weeks of age at the time of the first study vaccination.
• Written informed consent obtained from the parent or guardian of the subject who is of legal age
• Healthy subjects as established by medical history and clinical examination before entering into the study.
• In South Africa, birth weight > 2000 grams or if weight unknown, gestation period > 36 weeks.

Exclusion Criteria:

• Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine(s) within 30 days preceding the first dose of study vaccine, or planned use during the study period.
• Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product
• Planned administration of a vaccine not foreseen by the study protocol within 14 days before each dose of study vaccine(s) and ending 14 days after.
• Chronic administration (defined as more than 14 days) of immunosuppressants since birth.
• History of use of experimental rotavirus vaccine.
• Previous routine vaccination except Bacille Calmette-Guérin (BCG), hepatitis B virus (HBV) and oral poliovirus (OPV) vaccination at birth
• Any clinically significant history of chronic gastrointestinal disease including any uncorrected congenital malformation of the gastrointestinal tract, intussusception or other medical condition determined to be serious by the investigator.
• Any confirmed or suspected immunosuppressive or immunodeficient condition based on medical history and physical examination
• History of allergic disease or reaction likely to be exacerbated by any component of the vaccine.
• Acute disease at the time of enrolment.
• Gastroenteritis within 7 days preceding the first study vaccine administration
• Previous confirmed occurrence of rotavirus gastroenteritis (RV GE).
• A family history of congenital or hereditary immunodeficiency.
• Administration of immunoglobulins and/or blood products since birth or planned administration during the study period.
• History of any neurologic disorders or seizures.
• Acute or chronic, clinically significant pulmonary, cardiovascular, hepatic or renal functional abnormality, as determined by physical examination or laboratory screening tests.